Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Costco Wholesale Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Costco Wholesale Corporation trades at $920.5 (market cap $406.34B). The key difference: Costco Wholesale Corporation is far larger — about 10.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | COST | |
|---|---|---|
Market Cap | $39.89B | $406.34B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $1.09K |
52-Week Low | $278.09 | $849.63 |
Enterprise Value | $38.15B | $394.48B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Costco (COST) trades at $916.25, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24 billion in 2025 and beat earnings expectations in recent quarters, though it missed in Q1 2026. Analyst consensus is strongly bullish with a $1,120 price target, supported by robust membership fee income and expanding margins.
The outlook remains positive due to consistent revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. The stock's current price is below the consensus target, suggesting potential upside if fundamental performance continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
